Global Alzheimer’s Therapeutics Market - Growth, Share, Opportunities, Pipeline Analysis, Competitive Analysis, and Forecast, 2016 - 2022, the Alzheimer’s therapeutics market was valued at USD 8,524.9 Mn in 2015, and is expected to reach USD 14,856.3 Mn by 2022, expanding at a CAGR of 8.02% from 2016 to 2022.
Browse Full Report Visit - http://www.acutemarketreports.com/report/alzheimers-therapeutics-market
Market Insights
Alzheimer’s disease is a progressive and currently incurable disease, and potential or supportive treatments have only emerged in the last decade. However, the currently available treatments are lacking in terms of efficacy or target-specificity. There are two types of drug classes used in treatment of Alzheimer’s disease, acetylcholinesterase (ACE) inhibitors and N-methyl-D-aspartate (NMDA) receptor antagonist. ACE inhibitors constitute of galantamine hydrochloride, donepezil hydrochloride and rivastigmine; NMDA receptor antagonist includes mematidine hydrochloride. Since the discovery of what plaques and tangles comprised in Alzheimer’s – amyloid β (Aβ) peptide and hyperphosphorylated tau (p-tau) protein respectively. An immense research and development has been carried out to develop therapeutics which can limit the rate of synthesis, reduce the toxicity or clear these factors from the brain. However, these attempts have been largely unsuccessful. Hence, considering the continuously rising Alzheimer prevalent population, as well as limited drugs available for treatment, Alzheimer’s disease presents a lucrative opportunity for an effective disease-modifying therapy to enter the market.
Alzheimer’s disease is a progressive and currently incurable disease, and potential or supportive treatments have only emerged in the last decade. However, the currently available treatments are lacking in terms of efficacy or target-specificity. There are two types of drug classes used in treatment of Alzheimer’s disease, acetylcholinesterase (ACE) inhibitors and N-methyl-D-aspartate (NMDA) receptor antagonist. ACE inhibitors constitute of galantamine hydrochloride, donepezil hydrochloride and rivastigmine; NMDA receptor antagonist includes mematidine hydrochloride. Since the discovery of what plaques and tangles comprised in Alzheimer’s – amyloid β (Aβ) peptide and hyperphosphorylated tau (p-tau) protein respectively. An immense research and development has been carried out to develop therapeutics which can limit the rate of synthesis, reduce the toxicity or clear these factors from the brain. However, these attempts have been largely unsuccessful. Hence, considering the continuously rising Alzheimer prevalent population, as well as limited drugs available for treatment, Alzheimer’s disease presents a lucrative opportunity for an effective disease-modifying therapy to enter the market.
Pipeline Analysis
The phase III drugs included in the pipeline analysis are ENA713 (Novartis Pharmaceuticals), Flutemetamol (18F) (GE Healthcare), LY450139 (Eli Lilly and Company), Dimebon (Medivation, Inc. & Pfizer, Inc.), and Aripiprazole/ BMS-337039 (Otsuka Pharmaceutical, Inc.). The overall pipeline for Alzeihmer’s is still very much dominated by small molecule drugs. However, there is still a considerable number of biologics in the pipeline with total 86 molecules, represented across all stages of development. According to market experts, the diversity of the several molecule types in the biologic group shows a certain level of innovation, with newer avenues being explored in accounts of recent failures. Overall, late stage clinical trials have highlighted very few molecules that could potentially replace current treatments during the forecast period.
The phase III drugs included in the pipeline analysis are ENA713 (Novartis Pharmaceuticals), Flutemetamol (18F) (GE Healthcare), LY450139 (Eli Lilly and Company), Dimebon (Medivation, Inc. & Pfizer, Inc.), and Aripiprazole/ BMS-337039 (Otsuka Pharmaceutical, Inc.). The overall pipeline for Alzeihmer’s is still very much dominated by small molecule drugs. However, there is still a considerable number of biologics in the pipeline with total 86 molecules, represented across all stages of development. According to market experts, the diversity of the several molecule types in the biologic group shows a certain level of innovation, with newer avenues being explored in accounts of recent failures. Overall, late stage clinical trials have highlighted very few molecules that could potentially replace current treatments during the forecast period.
Browse All Reports of This Category - http://www.acutemarketreports.com/category/pharmaceutical-market
Key Market Movements:
• Market experts suggest that a family history of Alzheimer’s increases the risk of disease development by 7.5 times
• The incidence and prevalence of Alzheimer’s disease doubles every five years after age 65 years
• Currently population of developed countries is at high risk of Alzheimer due to increasing geriatric population
• In developing countries from Asia Pacific and Latin America the awareness related to age-specific diseases such as dementia or Alzheimer is increasing
• Market experts suggest that a family history of Alzheimer’s increases the risk of disease development by 7.5 times
• The incidence and prevalence of Alzheimer’s disease doubles every five years after age 65 years
• Currently population of developed countries is at high risk of Alzheimer due to increasing geriatric population
• In developing countries from Asia Pacific and Latin America the awareness related to age-specific diseases such as dementia or Alzheimer is increasing
Chapter 1 Preface
1.1 Report Description
1.1.1 Study Purpose
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Methodology
1.1 Report Description
1.1.1 Study Purpose
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Methodology
Chapter 2 Executive Summary
2.1 Global Alzheimer’s Therapeutics Market Portaiture
2.2 Global Alzheimer’s Therapeutics Treament Market, by Drugs, 2015 (USD Mn)
2.3 Relativity Analysis: Global Alzheimer’s Therapeutics Market, by Geography, 2015 & 2022 (USD Mn)
2.1 Global Alzheimer’s Therapeutics Market Portaiture
2.2 Global Alzheimer’s Therapeutics Treament Market, by Drugs, 2015 (USD Mn)
2.3 Relativity Analysis: Global Alzheimer’s Therapeutics Market, by Geography, 2015 & 2022 (USD Mn)
Chapter 3 Alzheimer’s Therapeutics Market: Market Dynamics and Outlook
3.1 Alzheimer’s Therapeutics Market Overview
3.2 Market Inclination Insights
3.3 Market Dynamics
3.3.1 Drivers
3.3.2 Challenges
3.3.3 Opportunities
3.4 Attractive Investment Proposition
3.5 Competitive Analysis
3.5.1 Market Share Analysis: Global Alzheimer’s Therapeutics Market, 2015 (Value %)
3.1 Alzheimer’s Therapeutics Market Overview
3.2 Market Inclination Insights
3.3 Market Dynamics
3.3.1 Drivers
3.3.2 Challenges
3.3.3 Opportunities
3.4 Attractive Investment Proposition
3.5 Competitive Analysis
3.5.1 Market Share Analysis: Global Alzheimer’s Therapeutics Market, 2015 (Value %)
Chapter 4 Global Alzheimer’s Therapeutics Market, By Drugs
4.1 Preface
4.2 Memantine Hydrochloride
4.3 Donepezil Hydrochloride
4.4 Rivastigmine
4.5 Galantamine Hydrobromide
4.6 Pipeline Analysis
4.6.1 Projected sales of Phase III Drugs estimated till 2022 (US$ Mn)
4.6.1.1 ENA713
4.6.1.2 Flutemetamol (18F)
4.6.1.3 LY450139
4.6.1.4 Dimebon
4.6.1.5 Aripiprazole/ BMS-337039
4.6.2 Tabular Representation of Phase II and I Drugs
4.1 Preface
4.2 Memantine Hydrochloride
4.3 Donepezil Hydrochloride
4.4 Rivastigmine
4.5 Galantamine Hydrobromide
4.6 Pipeline Analysis
4.6.1 Projected sales of Phase III Drugs estimated till 2022 (US$ Mn)
4.6.1.1 ENA713
4.6.1.2 Flutemetamol (18F)
4.6.1.3 LY450139
4.6.1.4 Dimebon
4.6.1.5 Aripiprazole/ BMS-337039
4.6.2 Tabular Representation of Phase II and I Drugs
To Get Complete Report @ http://www.acutemarketreports.com/report/alzheimers-therapeutics-market
Chapter 5 Global Alzheimer’s Therapeutics Market, By Geography
5.1 Preface
5.2 North America
5.2.1 U.S
5.2.2 Canada
5.3 Europe
5.3.1 U.K
5.3.2 Germany
5.3.3 Rest of Europe
5.4 Asia Pacific
5.4.1 China
5.4.2 Japan
5.4.3 Rest of Asia Pacific
5.5 Rest of the World (RoW)
5.5.1 Latin America
5.5.2 Middle East and Africa
5.1 Preface
5.2 North America
5.2.1 U.S
5.2.2 Canada
5.3 Europe
5.3.1 U.K
5.3.2 Germany
5.3.3 Rest of Europe
5.4 Asia Pacific
5.4.1 China
5.4.2 Japan
5.4.3 Rest of Asia Pacific
5.5 Rest of the World (RoW)
5.5.1 Latin America
5.5.2 Middle East and Africa
Chapter 6 Company Profiles
6.1 Pfizer Inc.
6.1.1 Business Description
6.1.2 Financial Health and Budget Allocation
6.1.3 Product Portfolio
6.1.4 News Coverage
6.2 Novartis International AG
6.2.1 Business Description
6.2.2 Financial Health and Budget Allocation
6.2.3 Product Portfolio
6.1 Pfizer Inc.
6.1.1 Business Description
6.1.2 Financial Health and Budget Allocation
6.1.3 Product Portfolio
6.1.4 News Coverage
6.2 Novartis International AG
6.2.1 Business Description
6.2.2 Financial Health and Budget Allocation
6.2.3 Product Portfolio
About - Acute Market Reports :
Acute Market Reports is the most sufficient collection of market intelligence services online. It is your only source that can fulfill all your market research requirements.We provide online reports from over 100 best publishers and upgrade our collection regularly to offer you direct online access to the world’s most comprehensive and recent database with expert perceptions on worldwide industries, products, establishments and trends.
Acute Market Reports is the most sufficient collection of market intelligence services online. It is your only source that can fulfill all your market research requirements.We provide online reports from over 100 best publishers and upgrade our collection regularly to offer you direct online access to the world’s most comprehensive and recent database with expert perceptions on worldwide industries, products, establishments and trends.
Our team consists of highly motivated market research professionals and they are accountable for creating the groundbreaking technology that we utilize in our search engine operations to easily recognize the most current market research reports online.
Contact Us :
Name : Chris Paul
ACUTE MARKET REPORTS
Designation : Global Sales Manager
Toll Free(US/CANADA): +1-855-455-8662
Email : sales@acutemarketreports.com
Website : http://www.acutemarketreports.com
Our Blog :- http://www.pdfdevices.com/
